What is Ipamorelin?
Ipamorelin is a growth-hormone secretagogue that acts at the ghrelin receptor and has been studied in human volunteers and clinical-development contexts.
Proposed mechanism
It activates the growth-hormone secretagogue receptor, producing a growth-hormone response.
What has been published?
Healthy-volunteer pharmacokinetic and pharmacodynamic studies measured peptide exposure and GH response.
Current human evidence
Human studies confirm pharmacological activity but do not establish broad body-composition, recovery, sleep, cognition or longevity benefits.
Regulatory status
Ipamorelin is not an FDA-approved drug. FDA has highlighted immunogenicity and peptide-characterization concerns.
Possible areas of research interest
- Ghrelin-receptor biology
- Growth-hormone secretion
- Endocrine pharmacology
- Gastrointestinal motility research
Important limitations
- Human pharmacology does not equal proven clinical benefit
- Safety varies by route and context
- Long-term use in healthy people is not well characterized
- Marketing claims frequently run ahead of evidence
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.